摘要
目的观察诺和锐30(双时相门冬胰岛素)在2型糖尿病患者中的临床应用。方法将52例需用胰岛素的2型糖尿病患者随机分成治疗组(26例)和对照组(26例)。治疗组应用诺和锐30,对照组应用诺和灵30R,均为每日两次皮下注射。应用12周,观察两组的空腹血糖、餐后血糖、中餐前血糖及糖化血红蛋白在治疗前后的变化。结果两组的空腹血糖、餐后血糖、中餐前血糖及糖化血红蛋白较治疗前明显下降(P<0.05)。两组的空腹血糖、中餐前血糖、糖化血红蛋白下降值差异不明显(P>0.05),而餐后血糖的下降值有明显差别(P<0.05)。结论治疗组的餐后血糖有明显降低,而且低血糖发生率较低,对空腹血糖、中餐前血糖及糖化血红蛋白亦有降低,是2型糖尿病尤其以餐后血糖高为主的患者更适合应用。
Objective To observe BIAsp30g clinical application in patients with type 2 diabetes. Methods 52 patients with type 2 diabetes using insulin were randomly divided into the treatment group （26 patients） and the control group （26 patients）. The treatment group were treated with BIAsp30 and the control group were treated with BHI30 twice daily in rooming and evening. Through 12 weeks＂ observation, comparing the two groups in fasting Blood glucose （ FBG）, postprandial glucose （PPG） ,preprandlal glucose and HbAlc. Results The two groups blood glucoses and HbAlc had decreased distinctly after treatment（ P 〈 0.05 ） . The FBG and HbAlc＇s descendent level of the two groups had not distinct difference （ P 〉 0.05 ）. The PPG descendent level of treatment group had distinct difference （ P 〈 0.05 ）. Conclusion The PPG of the treatment group distinctly descend. The low glucoses＇ occurrence rate of the treatment group was much lower than the control group. The FBG and HbAlc also descend. BIAsp30 is more suitable for patients with type 2 diabetes, especially patients with high PPG.
出处
《医药论坛杂志》
2006年第22期12-13,16,共3页
Journal of Medical Forum
